MILLBRAE, Calif., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”

Nasdaq: NYAX rose 13.9% on Tuesday after announcing acquisition of IPS Group Inc. for $350 million.

Eikon Therapeutics NASDAQ: EIKN outlined its development strategy for selective PARP1 inhibitors and

Eikon Therapeutics, Inc. (EIKN) Discusses Advances in PARP1 Biology and Next-Generation PARP Inhibit

Dow Jones up 200 points on Wed. Estee Lauder & other top stocks record gains after reporting str

Chairman and Chief Executive Officer, Roger M. Perlmutter, M.D., Ph.D., will participate in a key op

Wedbush analyst Robert Driscoll maintains Eikon Therapeutics (NASDAQ:EIKN) with a Underperform an

MILLBRAE, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”

Selected 0.60 mg/m2 as the single dose for the TeLuRide-006 study going forward for patients randomi

MILLBRAE, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”

Eikon Therapeutics' (NASDAQ: EIKN - Get Free Report) lock-up period will end on Tuesday, August 4th.

US stocks mixed in midday trading, Nasdaq falls 0.48%, Dow up 0.19%, S&P 500 down 0.23%. Consume

Dow Jones up 400 points on Monday. Baker Hughes Co (BKR) shares rise after positive earnings and tec

"Treating the first patient in TeLuRide-008 is a significant milestone for Eikon as we continue

MILLBRAE, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (Eikon),

Presentations to cover updates across Eikon's clinical pipeline including:  Updated data from TeLuRi

Gainers Pulsenmore (NASDAQ:PLSM) shares increased by 171.2% to $10.47 during Monday's pre-marke

Gainers Shuttle Pharmaceuticals (NASDAQ:SHPH) shares moved upwards by 66.9% to $6.31 during Thursda

Eikon Therapeutics, Inc. (NASDAQ:EIKN) ("Eikon"), a late-stage clinical biopharmaceutical co

Addition reflects Eikon's progress as a publicly traded company and increasing visibility within the

Eikon Therapeutics is initiated with a cautious buy, leveraging industry-leading management and a ro

MILLBRAE, Calif., June 08, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”

TeLuRide-005, a Phase 2 trial of EIK1001 in first-line patients with stage 4 NSCLC completed enrollm

Presentations to cover progress across Eikon's most advanced clinical-stage programs Updated data wi

ZBRA, VSTS, AMBQ, VPG, BAK, PACS, LOT, EIKN, DDD, WEN, SIBN post significant gains on better-than-ex

Wedbush analyst Robert Driscoll maintains Eikon Therapeutics (NASDAQ:EIKN) with a Underperform an

Eikon Therapeutics (NASDAQ:EIKN) reported quarterly losses of $(2.46) per share which beat the analy

MILLBRAE, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”)

U.S. stock futures mixed with Dow futures down 0.1%. Domino's Pizza misses earnings expectations

Wedbush analyst Robert Driscoll reiterates Eikon Therapeutics (NASDAQ:EIKN) with a Underperform a

Closed upsized initial public offering in February 2026, raising $381 million in gross proceeds Comp

EIKN (NASDAQ: EIKN - Get Free Report) has received an average rating of "Moderate Buy" from the seve

Cantor Fitzgerald analyst Imogen Mansfield initiates coverage on Eikon Therapeutics (NASDAQ:EIKN)

JP Morgan analyst Brian Cheng initiates coverage on Eikon Therapeutics (NASDAQ:EIKN) with a Overw

Wall Street analysts changed outlook on top names. For all changes, upgrades, downgrades and initiat

B of A Securities analyst Jason Zemansky initiates coverage on Eikon Therapeutics (NASDAQ:EIKN) w

Mizuho analyst Joseph Catanzaro initiates coverage on Eikon Therapeutics (NASDAQ:EIKN) with a Out

Morgan Stanley analyst Sean Laaman initiates coverage on Eikon Therapeutics (NASDAQ:EIKN) with a

Wedbush analyst Robert Driscoll initiates coverage on Eikon Therapeutics (NASDAQ:EIKN) with a Und

Stock News Novo sues Hims over compounded weight-loss drugs: Novo Nordisk (NVO) filed suit to stop H

The U.S. is reportedly poised for a wave of significant IPOs, with Goldman Sachs projecting proceeds

Seven IPOs and six SPACs priced this week. Five IPOs and five SPACs submitted filings. Five IPOs are